Pirfenidone Nanoparticles Improve Corneal Wound Healing and Prevent Scarring Following Alkali Burn

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Chowdhury, Sushovan ^a   Guha, Rajdeep ^a   Trivedi, Ruchit ^b   Kompella, Uday B ^b   Konar, Aditya ^a   Hazra, Sarbani ^c  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b UNIVERSITY OF COLORADO   (United States)

^c WEST BENGAL UNIVERSITY OF ANIMAL AND FISHERY SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; NANOPARTICLE; PIRFENIDONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BURN SCAR; CAUSTIC BURN; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA BURN; CORNEA EPITHELIUM; DRUG FORMULATION; DRUG UPTAKE; EPITHELIZATION; FEMALE; FLUORESCENCE MICROSCOPY; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; WOUND HEALING;

ANIMALS; CORNEA; EYE BURNS; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; NANOPARTICLES; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; WOUND HEALING;

EID: 84881107028     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070528     Document Type: Article

References (28)

1. Whitcher JP, Srinivasan M, Upadhyay MP, (2001) Corneal Blindness: a global perspective. Bull W H O. 79: 214-221.
2. McGwin G Jr, Xie A, Owsley C, (2005) Rate of eye injury in the United States. Arch Ophthalmol 123: 970-976.
3. Wagoner MD, (1997) Chemical injuries of the eye: current concepts in pathophysiology and therapy. Surv Ophthalmol 41: 275-313.
4. Saika S, (2004) TGF-beta signal transduction in corneal wound healing as a therapeutic target. Cornea 23: S25-S30.
5. Zieske JD, Hutcheon AE, Guo X, Chung EH, Joyce NC, (2001) TGF-beta receptor types I and II are differentially expressed during corneal epithelial wound repair. Invest Ophthalmol Vis Sci 42: 1465-1471.
6. Jester JV, Moller-Pedersen T, Huang J, Sax CM, Kays WT, et al. (1999) The cellular basis of corneal transparency: evidence for 'corneal crystallins'. J Cell Sci 112: 613-622.
7. Lee BS, Margolin SB, Nowak RA, (1998) Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 83: 219-223.
8. Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, et al. (2001) Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 14: 453-460.
9. Di Sario A, Bendia E, Svegliati BG, Ridolfi F, Casini A, et al. (2002) Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 37: 584-591.
10. Iyer SN, Gurujeyalakshmi G, Giri SN, (1999) Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 291: 367-373.
11. Raghu G, Johnson WC, Lockhart D, Mageto Y, (1999) Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 159: 1061-1069.
12. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, et al. (2005) Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171: 1040-1047.
13. Kim H, Choi YH, Park SJ, Lee SY, Kim SJ, et al. (2010) Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels. Invest Ophthalmol Vis Sci 51: 3061-3066.
14. Zhong H, Sun G, Lin X, Wu K, Yu M, (2011) Evaluation of Pirfenidone as a New Postoperative Anti-scarring Agent in Experimental Glaucoma Surgery. Invest Ophthalmol Vis Sci 52: 3136-42.
15. Choi K, Lee K, Ryu S-W, Im M, Kook KH, et al. (2012) Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19. Molecular Vision 18: 1010-1020.
16. Sun G, Lin X, Zhong H, Yang Y, Qiu X, et al. (2011) Pharmacokinetics of pirfenidone after topical administration in rabbit eye. Molecular Vision 17: 2191-2196.
17. Trivedi R, Redente EF, Thakur A, Riches DW, Kompella UB, (2012) Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology 23: 505101 doi:10.1088/0957-4484/23/50/505101.
18. Guha R, Chowdhury S, Palui H, Mishra A, Basak S, et al. (2013) Doxorubicin-loaded MePEG-PCL nanoparticles for prevention of posterior capsular opacification. Nanomedicine (Epub ahead of print) 1-14. doi:10.2217/NNM.12.175.
19. Fantes FE, Hanna KD, Waring GO 3rd, Pouliquen Y, Thompson KP, et al (1990) Wound healing after excimer laser keratomileusis (photorefractive keratectomy) in monkeys. Arch Ophthalmol 108: 665-675.
20. Jester JV, Barry PA, Lind GJ, Petroll WM, Garana R, et al. (1994) Corneal keratocytes: in situ and in vitro organization of cytoskeletal contractile proteins. Invest Ophthalmol Vis Sci 35: 730-743.
21. Muller LJ, Pels L, Vrensen GF, (1995) Novel aspects of the ultrastructural organization of human corneal keratocytes. Invest Ophthalmol Vis Sci 36: 2557-2567.
22. Zieske JD, Guimaraes SR, Hutcheon AE, (2001) Kinetics of keratocyte proliferation in response to epithelial debridement. Exp Eye Res 72: 33-39.
23. Hassell JR, Birk DE, (2010) The molecular basis of corneal transparency. Experimental Eye Research 91: 326-335.
24. Shi Q, Liu X, Bai Y, Cui C, Li J, et al. (2011) In Vitro Effects of Pirfenidone on Cardiac Fibroblasts: Proliferation, Myofibroblast Differentiation, Migration and Cytokine Secretion. PLoS ONE 6(11): e28134 doi:10.1371/journal.pone.0028134.
25. Hisatomi K, Mukae H, Sakamoto N, Ishimatsu Y, Kakugawa T, et al. (2012) Pirfenidone inhibits TGF-β1-induced overexpression of collagen type I and heat shock protein 47 in A549 cells. BMC Pulmonary Medicine 12: 24 doi:10.1186/1471-2466-12-24.
26. Yang H, Tyagi P, Kadam RS, Holden CA, Kompella UB, (2012) Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano 6: 7595-606.
27. Seoane J, (2006) Escaping from the TGFb anti-proliferative control. Carcinogenesis 27: 2148-2156.
28. Haber M, Cao Z, Panjwani N, Bedenice D, Li WW, et al. (2003) Effects of growth factors (EGF, PDGF-BB and TGF-beta 1) on cultured equine epithelial cells and keratocytes: implications for wound healing. Vet Ophthalmol 6: 211-7.